Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![AI, artificial intelligence-GettyImages-2183748780]( "Powering AI And Synthetic Biology In Therapy Design")
Powering AI And Synthetic Biology In Therapy Design2/27/2026AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.
-
![Mesenchymal stem cells MSCs, Medicinal signaling cells-GettyImages-2189923819]( "Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real")
Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real2/18/2026Mesoblast's Silviu Itescu shares how two decades of rigorous science and manufacturing turned allogeneic MSCs into the first FDA-approved cell therapy while building a scalable platform for inflammatory diseases such as GvHD, back pain, and heart failure.
-
![Rising arrows scalability-gettyimage117247268]( "Disciplined CGT Will Win On 2026 Regulatory Flexibility")
Disciplined CGT Will Win On 2026 Regulatory Flexibility1/29/2026Wilson Bryan, M.D., and Daniela Drago, Ph.D., RAC, joined our our first Cell & Gene Live of 2026 to unpack what a more mature era of regulatory oversight means for sponsors.
-
![planning, progress, forward thinking-GettyImages-2245382606]( "ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026")
ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 20261/12/2026ARM's Tim Hunt outlines how smarter regulation, evolving payment models, and global competition are reshaping CGT into a more accessible and commercially sustainable industry.
-
![2026 creative design-GettyImages-2226949048]( "Global Shifts And Strategic Resilience Will Shape CGT In 2026")
Global Shifts And Strategic Resilience Will Shape CGT In 20261/7/2026Dr. Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, and Ali Pashazadeh, Founder of Treehill Partners share why CGT developers are now navigating a landscape defined not only by technological innovation but also by geography, regulatory agility, and investment dynamics.
-
![12-11-25 CGL Social Sharing 1200x1200]( "Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost")
Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost12/18/2025Our recent Cell & Gene Live, Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing, explored how developers and CDMOs are navigating multi-modal manufacturing decisions, balancing cost, capacity, risk, and long-term commercial viability.
-
![blood transfusion, world blood donor day, red cross-GettyImages-1499936573]( "CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B")
CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B12/12/2025CSL's Dr. Deborah Long and Diego Sacristan highlight HEMGENIX's five-year Phase 3 data as a watershed for hemophilia B gene therapy.
-
![Holding Puzzle Pieces-GettyImages-514165406]( "Cell 2025, Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional")
Cell 2025, Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional12/10/2025True scalability and global-ready CGT manufacturing depends on platformization that tightly integrates MES, ERP, LIMS, and related systems into a harmonized, leadership-driven digital backbone that treats data as a strategic asset.
-
![10-16-25 CGL Social Sharing 1200x1200 (1)]( "Why Early Manufacturing Decisions in Cell & Gene Therapy Matter")
Why Early Manufacturing Decisions in Cell & Gene Therapy Matter11/20/2025Our Cell & Gene Live covered why early manufacturing decisions in cell and gene therapy are crucial, as they set the stage for future scalability, quality, and commercial success.
-
![10-16-25 CGL Social Sharing 1200x1200]( "How Early Manufacturing Decisions Shape Long-Term Success")
How Early Manufacturing Decisions Shape Long-Term Success10/27/2025Early manufacturing choices in cell and gene therapy shape long-term clinical and commercial success, so leaders from Allogene and Verismo emphasized that both autologous and allogeneic developers should prioritize process simplicity, risk-based decision-making, and adaptable manufacturing as therapies move from concept to clinic.
